Laurus Labs IPO

Laurus Labs IPO Laurus Labs Logo

Laurus Labs is a leading research and development driven pharmaceutical company in India, with a leadership position in generic active pharmaceutical ingredients (APIs) for select, high-growth therapeutic areas of antiretrovirals (ARVs) and Hepatitis C. The company is one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing “donor-funded access-tomedicines markets” of Sub-Saharan Africa, South-East Asia and Latin America. During the financial year 2016, Laurus sold its APIs in 32 countries. The company also manufactures APIs in oncology and other therapeutic areas.

The company operates in four business lines: Generics – APIs, Generics – FDFs, Synthesis and Ingredients. The Generics – API business comprises the development, manufacture and sale of APIs and advanced intermediates. The Generics – FDF business comprises the development and manufacture of oral solid formulations while the Synthesis business includes contract development and manufacturing services for global pharmaceutical companies. The Ingredients business comprises the manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors. Laurus Labs has launched 59 products since its inception in 2005. Its key customers include Aspen Pharmacare Limited, Aurobindo Pharma Limited, Cipla Limited, Mylan Laboratories Limited, NATCO Pharma Limited and Strides Shasun Limited. The company claims that nine out of the 10 largest generic pharmaceutical companies in the world, by revenue, were its customers during the financial year 2016.

As of 30 June 2016, Laurus Labs employed 587 and 12 scientists at its R&D centers in Hyderabad and Greater Boston, constituting 25% of its total employee strength. The company spent INR906.52 million towards R&D activities during the financial year 2016, or 5.1%, of its total revenues. As of 30 June 2016, the company owned 32 patents and had 150 pending patent applications, in several countries.

Laurus Labs currently operates three manufacturing facilities in Visakhapatnam, Andhra Pradesh. Two of its facilities manufacture APIs and ingredients, while the third facility is for the manufacturing of APIs and FDFs. It also has a kilo lab near Hyderabad, Telangana. The company is also in the process of setting up two additional manufacturing facilities, one for potent APIs (expected to commence operations by 31 December 2016) and the other for APIs, intermediates and ingredients (expected to commence construction during the financial year 2017).

Promoter of Laurus Labs: Dr. Satyanarayana Chava, Naga Rani Chava, Dr. Raju Srihari Kalidindi, Ravi Kumar Vivi, and Dr. Lakshmana Rao CV

Laurus Labs IPO details
Subscription Dates 6 – 8 December 2016
Price Band INR426 – 428 per share
Fresh issue Up to INR3 billion (INR300 crore)
Offer For Sale 24,107,440 shares or INR10.31 billion (INR1031.79 crore at upper price band)
Total IPO size INR13.31 billion (INR1331.79 crore at upper price band)
Minimum bid (lot size) 35 shares
Face Value  INR10 per share
Retail Allocation 35%
Listing On BSE, NSE


Laurus Labs’ consolidated financial performance (in INR crore)

  FY2014 FY2015 FY2016
Total revenue 1,168.5 1,360.6 1,791.3
Total expenses 950.8 1,126.4 1,411.5
Profit after tax 97.2 68.3 132.6


Laurus Labs Ltd 
2nd Floor, Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad 500034

Phone: +91 40 3980 4333
Fax: +91 40 3980 4320
Email: [email protected]

Karvy Computershare Private Limited
Karvy House, 46, Avenue 4, Street No. 1,
Banjara Hills, Hyderabad – 500 034
Andhra Pradesh, India

Phone: +91 40 23312454
Fax: +91 40 23311968
[email protected]

Laurus Labs IPO Subscription Details

Category Shares offered Subscription (no. of times, at 6 PM ) 
Day 1 Day 2 Day 3
QIB  6,174,544 0.70  1.01  10.53
NII  4,623,879 0.16 0.53 3.57
Retail  10,789,051 0.09 0.39 1.56
Employee  323,834 0.03 0.98 1.69
Total  21,911,308  0.28 0.60 4.52

Laurus Labs IPO allotment status will be available on available on Karvy Computershare’s website. Click on this link to get allotment status. You can also check allotment status using application number on this link.

IPO Opening Date: 6 December 2016

IPO Closing Date: 8 December 2016

Finalisation of Basis of Allotment: 14 December 2016

Initiation of refunds: 15 December 2016

Transfer of shares to demat accounts: 16 December 2016

Listing Date: 19 December 2016

Listing Price on NSE: INR489.9 per share (Profit of 14.5% on IPO price)

Closing Price on NSE: INR480 per share (Profit of 12.2% on IPO price)


  1. Bhai apply to tab karoge jab ye issue aayego. I’m hearing Sheela Foam is also coming but it is clearly a difficult time for IPOs so bankers and promoters are thinking hard before bringing their offers.

  2. Approval of seven IPOs worth Rs 2,500 crore might lapse in the next three months if they don’t hit the market, data show. Timelines of other big-ticket IPOs gearing up to hit the market could also get impacted, said experts. Warburg Pincus-backed generic drug maker Laurus Labs (estimated issue amount of Rs 1,000 crore) and Sheela Foam (Rs 510 crore) reportedly aimed to hit the market with their offerings by November-end. IPOs worth Rs 24,500 crore have hit the market in 2016.

  3. Now no scope of confusion. Instead of gambling money on Sheela, I’ll invest in Laurus. Pharma has been better and rewarded investors. Moreover, it is one of the sectors which will gain from a weaker rupee.

    • Only a small % is assigned to employees by few companies. The discount given to the employees in not necessarily the true value of the share. The discount is handed to the employees to increase their engagement with the company and also showcase to retail investors the confidence that employees have on company’s future performance.

  4. A firm endorsement of Laurus labs future prospects & readiness by its own employees with their quota getting 98% subscription by end of Day-2 – the RIIs should take note & ramp up their bids tomorrow.

    The QIB sentiment is of course crystal clear with an unlikely 100% subscription by Day-2 itself


  6. The real game changer will be NSE IPO. But don’t just apply in the IPO because the whole world will apply and only a few will get and that also just one lot. Keep an eye on IFCI, more gains next week.

  7. My dear fellow investors, I got allotment in two applications. Now my question is does it make sense to book profits on listing or hold it. If someone can update the latest GMP, that would be great too.

  8. *****Happy New Year*****

    May 2017 bring even more success and prosperity for IPO investors. We have a long list of upcoming IPOs and I’m personally waiting for IPO of BSE, NSE, CDSL, CL Educate and D Mart.


Please enter your comment!
Please enter your name here